RU2453554C2 - Substituted extratriene derivtives as 17beta hsd inhibitors - Google Patents
Substituted extratriene derivtives as 17beta hsd inhibitors Download PDFInfo
- Publication number
- RU2453554C2 RU2453554C2 RU2009124589/04A RU2009124589A RU2453554C2 RU 2453554 C2 RU2453554 C2 RU 2453554C2 RU 2009124589/04 A RU2009124589/04 A RU 2009124589/04A RU 2009124589 A RU2009124589 A RU 2009124589A RU 2453554 C2 RU2453554 C2 RU 2453554C2
- Authority
- RU
- Russia
- Prior art keywords
- trien
- compound
- group
- alkyl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
FIELD: chemistry.
SUBSTANCE: invention relates to substituted extratriene derivatives of general formula (values of radicals are given in the claim), useful in therapy, especially for treating and/or preventing steroid hormone-dependent disorders which require inhibition of 17β-hydroxysteroid dehydrogenase (17-HSD) enzyme type 1, type 2 and/or type 3, as well as salts thereof, pharmaceutical preparations containing said compounds, as well as methods of producing said compounds.
EFFECT: improved method.
41 cl, 98 ex
Description
Claims (41)
где -X-A-Y- совместно обозначают -CO-NR4-;
R1 выбран из группы, состоящей из:
(a) -B(OR9)(OR10),
(b) -CO-NR7R8, и
(c) -NR7R8,
где R7, R8, R9 и R10 независимо выбраны из группы, состоящей из:
(a) -Н,
(b) замещенного арила или арил-(С1-С14)алкила, и
(c) необязательно замещенного гетероарила,
n равно 2 или 3;
R11 представляет собой Н;
R12 и R13 совместно обозначают =O, или R12 и R13 каждый по отдельности представляет собой F;
R2 и R4 независимо выбраны из:
(a) -Н;
(b) необязательно замещенного -(С1-С14)алкила,
(c) необязательно замещенного арила или арил-(С1-С14)алкила, и
(d) необязательно замещенного гетероарила или гетероарил-(С1-С14)алкила;
или R2 и R4 вместе с атомом азота, к которому R2 и R4 присоединены, образуют гетероциклическое 6-членное кольцо, которое является насыщенным; которое необязательно содержит 1 дополнительный гетероатом, выбранный из О, причем количество дополнительных атомов О составляет 0 или 1;
и все его стереоизомеры, фармацевтически приемлемые соли и сольваты.1. The compound of General formula I
where -XAY- together mean -CO-NR 4 -;
R 1 selected from the group consisting of:
(a) -B (OR 9 ) (OR 10 ),
(b) -CO-NR 7 R 8 , and
(c) -NR 7 R 8 ,
where R 7 , R 8 , R 9 and R 10 are independently selected from the group consisting of:
(a) -H,
(b) substituted aryl or aryl- (C 1 -C 14 ) alkyl, and
(c) optionally substituted heteroaryl,
n is 2 or 3;
R 11 represents H;
R 12 and R 13 collectively mean = O, or R 12 and R 13 each individually represents F;
R 2 and R 4 are independently selected from:
(a) -H;
(b) optionally substituted - (C 1 -C 14 ) alkyl,
(c) optionally substituted aryl or aryl- (C 1 -C 14 ) alkyl, and
(d) optionally substituted heteroaryl or heteroaryl- (C 1 -C 14 ) alkyl;
or R 2 and R 4 together with the nitrogen atom to which R 2 and R 4 are attached form a heterocyclic 6-membered ring that is saturated; which optionally contains 1 additional heteroatom selected from O, wherein the number of additional O atoms is 0 or 1;
and all its stereoisomers, pharmaceutically acceptable salts and solvates.
или его фармацевтически приемлемая соль.2. The compound of General formula I according to claim 1, which is an optically pure enantiomer of the formula (II)
or a pharmaceutically acceptable salt thereof.
или его фармацевтически приемлемая соль.3. The compound of General formula I according to claim 1, which is an optically pure enantiomer of formula (III)
or a pharmaceutically acceptable salt thereof.
(а) -Н;
(b) -(С1-С12)алкила, который необязательно замещен одним заместителем, выбранным из -OR14;
(c) арила и арил-(С1-С12)алкила, где арильный фрагмент необязательно замещен одним или несколькими заместителями, независимо выбранными из группы, состоящей из галогена и -OR14; количество указанных заместителей составляет 2 для галогена и 2 для любой комбинации указанных заместителей;
или где арильный фрагмент замещен двумя группами, которые присоединены к соседним атомам углерода, и объединены в одну насыщенную циклическую 5-членную кольцевую систему, содержащую 2 гетероатома, выбранных из О;
(d) гетероарила и гетероарил-(С1-С12)алкила, где гетероарильный фрагмент необязательно замещен одним заместителем, выбранным из -(С1-С6)алкила;
или R2 и R4 вместе с атомом азота, к которому R2 и R4 присоединены, образуют гетероциклическое 6-членное кольцо, которое является насыщенным, которое содержит 1 дополнительный гетероатом, выбранный из О;
где R14 независимо выбран из группы, состоящей из -Н и -(С1-С4)-алкила;
и где n равно 2 или 3.4. The compound according to claim 1, where R 2 and R 4 are independently selected from:
(a) -H;
(b) - (C 1 -C 12 ) alkyl, which is optionally substituted with one substituent selected from —OR 14 ;
(c) aryl and aryl- (C 1 -C 12 ) alkyl, wherein the aryl moiety is optionally substituted with one or more substituents independently selected from the group consisting of halogen and —OR 14 ; the number of these substituents is 2 for halogen and 2 for any combination of these substituents;
or where the aryl moiety is substituted with two groups that are attached to adjacent carbon atoms and combined into one saturated 5-membered ring system containing 2 heteroatoms selected from O;
(d) heteroaryl and heteroaryl- (C 1 -C 12 ) alkyl, wherein the heteroaryl moiety is optionally substituted with one substituent selected from - (C 1 -C 6 ) alkyl;
or R 2 and R 4 together with the nitrogen atom to which R 2 and R 4 are attached form a heterocyclic 6-membered ring which is saturated, which contains 1 additional heteroatom selected from O;
where R 14 is independently selected from the group consisting of —H and - (C 1 -C 4 ) -alkyl;
and where n is 2 or 3.
(a) -Н,
(b) арила и арил-(С1-С12)алкила, где арильный фрагмент в арильной группе замещен одним или несколькими заместителями, независимо выбранными из группы, состоящей из -OR19, галоидированного -(С1-С6)алкила и -SO2NR20R21; число указанных заместителей составляет 1 или 2 для любой комбинации указанных заместителей;
(с) гетероарила, в котором гетероарильный фрагмент необязательно замещен одним или несколькими заместителями, независимо выбранными из оксогруппы;
где R19 представляет собой -(С1-С4)алкил, или где R20 и R21 вместе с атомом азота, к которому они присоединены, образуют гетероциклическое 6-членное кольцо, содержащее 1 дополнительный гетероатом, выбранный из О.5. The compound according to claim 1, where R 7 , R 8 , R 9 and R 10 are independently selected from the group consisting of:
(a) -H,
(b) aryl and aryl- (C 1 -C 12 ) alkyl, wherein the aryl moiety in the aryl group is substituted with one or more substituents independently selected from the group consisting of —OR 19 , halogenated - (C 1 -C 6 ) alkyl, and -SO 2 NR 20 R 21 ; the number of said substituents is 1 or 2 for any combination of said substituents;
(c) heteroaryl, in which the heteroaryl moiety is optionally substituted with one or more substituents independently selected from the oxo group;
where R 19 represents - (C 1 -C 4 ) alkyl, or where R 20 and R 21 together with the nitrogen atom to which they are attached form a 6-membered heterocyclic ring containing 1 additional heteroatom selected from O.
(a) -В(ОН)2,
(b) -CO-NR7R8, и
(c) -NR7R8.6. The compound according to claim 1, where R 1 selected from the group consisting of:
(a) -B (OH) 2 ,
(b) -CO-NR 7 R 8 , and
(c) -NR 7 R 8 .
(a) -Н,
(b) фенила и фенил-(С1-С4)алкила, где фенильный фрагмент необязательно замещен 1 или 2 заместителями, независимо выбранными из группы, состоящей из -OR19, галоидированного-(С1-С4)алкила и -SO2NR20R21;
(c) гетероарила, в котором гетероарильный фрагмент необязательно замещен 2 оксогруппами;
где R19 представляет собой -(С1-С4)алкил, или где R20 и R21 вместе с атомом азота, к которому они присоединены, образуют гетероциклическое 6-членное кольцо, содержащее 1 дополнительный гетероатом, выбранный из О.8. The compound of claim 6, wherein R 1 is —NR 7 R 8 , and R 7 and R 8 are independently selected from the group consisting of:
(a) -H,
(b) phenyl and phenyl- (C 1 -C 4 ) alkyl, wherein the phenyl moiety is optionally substituted with 1 or 2 substituents independently selected from the group consisting of -OR 19 , halogenated- (C 1 -C 4 ) alkyl and -SO 2 NR 20 R 21 ;
(c) heteroaryl in which the heteroaryl moiety is optionally substituted with 2 oxo groups;
where R 19 represents - (C 1 -C 4 ) alkyl, or where R 20 and R 21 together with the nitrogen atom to which they are attached form a 6-membered heterocyclic ring containing 1 additional heteroatom selected from O.
(a) -Н,
(b) -(С1-С6)алкила и -(С1-С6)циклоалкила, которые необязательно замещены 1 заместителем, выбранным из -OR14;
(c) фенила и фенил-(С1-С4)алкила, где фенильный фрагмент необязательно замещен 2 заместителями, независимо выбранными из группы, состоящей из галогена и -OR14, или
где фенильный фрагмент замещен двумя группами, которые присоединены к соседним атомам углерода и объединены в одну насыщенную циклическую 5-членную кольцевую систему, содержащую 2 гетероатома, выбранных из О;
(d) гетероарила и гетероарил-(С1-С4)алкила, где гетероарильный фрагмент необязательно замещен 1 заместителем, выбранным из -(С1-С6)алкила;
или R2 и R4 вместе с атомом азота, к которому R2 и R4 присоединены, образуют гетероциклическое 6-членное кольцо, которое является насыщенным, которое необязательно содержит 1 дополнительный гетероатом, выбранный из О, и количество атомов О составляет 0 или 1;
где R14 выбран из группы, состоящей из -Н и -(С1-С4)алкила.9. The compound according to claim 1, where R 2 and R 4 are independently selected from:
(a) -H,
(b) - (C 1 -C 6 ) alkyl; and - (C 1 -C 6 ) cycloalkyl, which are optionally substituted with 1 substituent selected from —OR 14 ;
(c) phenyl and phenyl- (C 1 -C 4 ) alkyl, wherein the phenyl moiety is optionally substituted with 2 substituents independently selected from the group consisting of halogen and —OR 14 , or
where the phenyl fragment is substituted by two groups that are attached to adjacent carbon atoms and combined into one saturated cyclic 5-membered ring system containing 2 heteroatoms selected from O;
(d) heteroaryl and heteroaryl- (C 1 -C 4 ) alkyl, wherein the heteroaryl moiety is optionally substituted with 1 substituent selected from - (C 1 -C 6 ) alkyl;
or R 2 and R 4 together with the nitrogen atom to which R 2 and R 4 are attached form a heterocyclic 6-membered ring which is saturated, which optionally contains 1 additional heteroatom selected from O, and the number of O atoms is 0 or 1 ;
where R 14 is selected from the group consisting of —H and - (C 1 -C 4 ) alkyl.
10. The compound according to claim 1, where n is 2 and the compound is an optically pure enantiomer of formula (III-b)
11. The compound according to claim 1, where n is 3 and the compound is an optically pure enantiomer of the formula (II-b)
R1 представляет собой -CO-NR7R8, где R7 и R8 представляют собой -Н;
-X-A-Y- совместно обозначают -CO-NR4-;
R11 представляет собой -Н;
R12 и R13 совместно обозначают =O, или R12 и R13 каждый по отдельности представляет собой F; и
n равно 2.14. The compound according to claim 1, where
R 1 represents —CO — NR 7 R 8 wherein R 7 and R 8 are —H;
-XAY- together represent -CO-NR 4 -;
R 11 represents —H;
R 12 and R 13 collectively mean = O, or R 12 and R 13 each individually represents F; and
n is 2.
R1 представляет собой -В(ОН)2;
-X-A-Y- совместно обозначают -CO-NR4-;
R11 представляет собой -Н;
R12 и R12 совместно обозначают =O, или R12 и R13 каждый по отдельности представляет собой F; и
n равно 2 или 3.15. The compound according to claim 1, where
R 1 represents —B (OH) 2 ;
-XAY- together represent -CO-NR 4 -;
R 11 represents —H;
R 12 and R 12 together are ═O, or R 12 and R 13 are each individually F; and
n is 2 or 3.
R1 представляет собой -NR7R8;
-X-A-Y- совместно обозначают -CO-NR4-;
R11 представляет собой -Н;
R12 и R13 совместно обозначают =O; и
n равно 3.16. The compound according to claim 1, where
R 1 represents —NR 7 R 8 ;
-XAY- together represent -CO-NR 4 -;
R 11 represents —H;
R 12 and R 13 together are = O; and
n is 3.
(a) -Н,
(b) фенила и фенил-(С1-С2)алкила, где фенильный фрагмент необязательно замещен 1 или 2 заместителями, независимо выбранными из группы, состоящей из
-OR19, галоидированного -(С1-С4)алкила и -SO2NR20R21;
(c) гетероарила, в котором гетероарильный фрагмент выбран из группы, состоящей из хинолинила и бензотиенила, где гетероарильный фрагмент необязательно замещен 2 оксогруппами;
где R19 представляет собой -(С1-С4)алкил, или где R20 и R21 вместе с атомом азота, к которому они присоединены, образуют гетероциклическое 6-членное кольцо, содержащее 1 дополнительный гетероатом, выбранный из О.17. The compound according to clause 16, where R 7 and R 8 are independently selected from:
(a) -H,
(b) phenyl and phenyl- (C 1 -C 2 ) alkyl, wherein the phenyl moiety is optionally substituted with 1 or 2 substituents independently selected from the group consisting of
-OR 19 halogenated - (C 1 -C 4 ) alkyl; and -SO 2 NR 20 R 21 ;
(c) heteroaryl in which the heteroaryl moiety is selected from the group consisting of quinolinyl and benzothienyl, wherein the heteroaryl moiety is optionally substituted with 2 oxo groups;
where R 19 represents - (C 1 -C 4 ) alkyl, or where R 20 and R 21 together with the nitrogen atom to which they are attached form a 6-membered heterocyclic ring containing 1 additional heteroatom selected from O.
(a) -Н,
(b) -(С1-С4)-алкила, который необязательно замещен -OR14,
(c) -(С1-С6)-циклоалкила,
(d) фенила и фенил-(С1-С2)алкила, где фенильный фрагмент необязательно замещен 2 заместителями, независимо выбранными из группы, состоящей из галогена и -OR14, или
где фенильный фрагмент замещен двумя группами, которые присоединены к соседним атомам углерода, и объединены в насыщенную циклическую 5-или 6-членную кольцевую систему, содержащую 2 гетероатома, выбранных из О;
(e) гетероарила и гетероарил-(С1-С2)алкила, где гетероарильный фрагмент выбран из группы, состоящей из пиридинила, индолила и тиазолила, и где гетероарильный фрагмент необязательно замещен -(С1-С4)алкилом;
или R2 и R4 вместе с атомом азота, к которому R2 и R4 присоединены, образуют гетероциклическое 6-членное насыщенное кольцо, которое необязательно содержит 1 дополнительный гетероатом, выбранный из О;
где R14 выбран из группы, состоящей из -Н и -(С1-С4)алкила.18. The compound according to claim 1, where R 2 and R 4 are independently selected from:
(a) -H,
(b) - (C 1 -C 4 ) -alkyl, which is optionally substituted with —OR 14 ,
(c) - (C 1 -C 6 ) cycloalkyl,
(d) phenyl and phenyl- (C 1 -C 2 ) alkyl, wherein the phenyl moiety is optionally substituted with 2 substituents independently selected from the group consisting of halogen and —OR 14 , or
where the phenyl fragment is substituted by two groups that are attached to adjacent carbon atoms, and combined into a saturated cyclic 5 or 6 membered ring system containing 2 heteroatoms selected from O;
(e) heteroaryl and heteroaryl- (C 1 -C 2 ) alkyl, wherein the heteroaryl moiety is selected from the group consisting of pyridinyl, indolyl and thiazolyl, and where the heteroaryl moiety is optionally substituted with (C 1 -C 4 ) alkyl;
or R 2 and R 4 together with the nitrogen atom to which R 2 and R 4 are attached form a heterocyclic 6-membered saturated ring, which optionally contains 1 additional heteroatom selected from O;
where R 14 is selected from the group consisting of —H and - (C 1 -C 4 ) alkyl.
№3 - 15бета-{3-[(5-метил-1,3-тиазол-2-ил)амино]-3-оксопропил}-17-оксоэстра-1(10),2,4-триен-3-карбоксамида,
№8 - 17,17-дифтор-15бета-{3-[(5-метил-1,3-тиазол-2-ил)амино]-3-оксопропил}эстра-1(10),2,4-триен-3-карбоксамида,
№11 - [15альфа-{3-[(5-метил-1,3-тиазол-2-ил)амино]-3-оксопропил}-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№12 - [15альфа-{4-[(3,4-дигидроксибензил)амино]-4-оксобутил}-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№13 - [15альфа-[4-(1,3-бензодиоксол-5-иламино)-4-оксобутил]-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№16 - [15альфа-{4-[(5-метил-1,3-тиазол-2-ил)амино]-4-оксобутил}-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№17 - [15альфа-[4-(циклогексиламино)-4-оксобутил]-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№19 - [15альфа-{4-[(1,3-бензодиоксол-5-илметил)амино]-4-оксобутил}-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№20 - [17-оксо-15альфа-(4-оксо-4-пиперидин-1-илбутил)эстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№22 - [15альфа-{4-[бензил(метил)амино]-4-оксобутил}-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№23 - [15альфа-[4-(бензиламино)-4-оксобутил]-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№26 - [15альфа-(4-{[2-(3,4-диметоксифенил)этил](метил)амино}-4-оксобутил)-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№30 - [(15бета-(3-{[2-(7-метил-1Н-индол-3-ил)этил]амино}-3-оксопропил)-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№31 - [(15бета-{3-[(5-метил-1,3-тиазол-2-ил)амино]-3-оксопропил}-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№32 - [(15бета-[3-(циклогексиламино)-3-оксопропил]-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№33 - [(15бета-(3-морфолин-4-ил-3-оксопропил)-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№34 - [(15бета-{3-[(1,3-бензодиоксол-5-илметил)амино]-3-оксопропил}-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№35 - [17-оксо-15бета-(3-оксо-3-пиперидин-1-илпропил)эстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№37 - [(15бета-{3-[бензил(метил)амино]-3-оксопропил)-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№39 - [(15бета-[3-(диэтиламино)-3-оксопропил]-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№45 - [(15бета-[3-(1,3-бензодиоксол-5-иламино)-3-оксопропил]-17-оксоэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№48 - [15альфа-[4-(циклогексиламино)-4-оксобутил]-17,17-дифторэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№49 - [15альфа-[4-(диэтиламино)-4-оксобутил]-17,17-дифторэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№50 - [15альфа-{4-[(1,3-бензодиоксол-5-илметил)амино]-4-оксобутил}-17,17-дифторэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№51 - [15альфа-(4-{[2-(3,4-диметоксифенил)этил](метил)амино}-4-оксобутил)-17,17-дифторэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№53 - [17,17-дифтор-15альфа-{4-оксо-4-[(пиридин-3-илметил)амино]-бутил}эстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№54 - [15альфа-[4-(бензиламино)-4-оксобутил]-17,17-дифторэстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№57 - [17,17-дифтор-15альфа-(4-оксо-4-пиперидип-1-илбутил)эстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№58 - [17,17-дифтор-15бета-{3-[(5-метил-1,3-тиазол-2-ил)амино]-3-оксопропил}эстра-1(10),2,4-триен-3-ил]бороновой кислоты,
№75 - 3-{[3-метокси-5-(трифторметил)фенил]амино}-15альфа-(4-морфолин-4-ил-4-оксобутил)эстра-1(10)2,4-триен-17она,
№76 - 15альфа-(4-морфолин-4-ил-4-оксобутил)-3-{[3-(морфолин-4-илсульфонил)фенил]амино}эстра-1(10),2,4-триен-17она,
№83 - 15альфа-(4-морфолин-4-ил-4-оксобутил)-3-(хинолин-3-иламино)эстра-1(10),2,4-триен-17-она,
№91 - 3-[(1,1-диоксидо-1-бензотиен-6-ил)амино]-15альфа-(4-морфолин-4-ил-4-оксобутил)эстра-1(10),2,4-триен-17-она,
№98 - 3-(бензиламино)-15альфа-(4-морфолин-4-ил-4-оксобутил)эстра-1(10),2,4-триен-17-она
и любые их фармацевтически приемлемые соли.19. The compound according to claim 1, selected from the group consisting of the following compounds, illustrated by examples:
No. 3 - 15beta - {3 - [(5-methyl-1,3-thiazol-2-yl) amino] -3-oxopropyl} -17-oxoestra-1 (10), 2,4-triene-3-carboxamide ,
No. 8 - 17,17-difluoro-15 beta- {3 - [(5-methyl-1,3-thiazol-2-yl) amino] -3-oxopropyl} estra-1 (10), 2,4-trien- 3-carboxamide,
No. 11 - [15 alpha- {3 - [(5-methyl-1,3-thiazol-2-yl) amino] -3-oxopropyl} -17-oxoestra-1 (10), 2,4-triene-3- sludge] boronic acid,
No. 12 - [15 alpha- {4 - [(3,4-dihydroxybenzyl) amino] -4-oxobutyl} -17-oxoestra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 13 - [15alpha- [4- (1,3-benzodioxol-5-ylamino) -4-oxobutyl] -17-oxoestra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 16 - [15 alpha- {4 - [(5-methyl-1,3-thiazol-2-yl) amino] -4-oxobutyl} -17-oxoestra-1 (10), 2,4-triene-3- sludge] boronic acid,
No. 17 - [15alpha- [4- (cyclohexylamino) -4-oxobutyl] -17-oxoestra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 19 - [15 alpha- {4 - [(1,3-benzodioxol-5-ylmethyl) amino] -4-oxobutyl} -17-oxoestra-1 (10), 2,4-trien-3-yl] boronic acid ,
No. 20 - [17-oxo-15alpha- (4-oxo-4-piperidin-1-ylbutyl) estra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 22 - [15 alpha- {4- [benzyl (methyl) amino] -4-oxobutyl} -17-oxoestra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 23 - [15alpha- [4- (benzylamino) -4-oxobutyl] -17-oxoestra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 26 - [15alpha- (4 - {[2- (3,4-dimethoxyphenyl) ethyl] (methyl) amino} -4-oxobutyl) -17-oxoestra-1 (10), 2,4-trien-3- sludge] boronic acid,
No. 30 - [(15beta- (3 - {[2- (7-methyl-1H-indol-3-yl) ethyl] amino} -3-oxopropyl) -17-oxoestra-1 (10), 2,4- trien-3-yl] boronic acid,
No. 31 - [(15beta- {3 - [(5-methyl-1,3-thiazol-2-yl) amino] -3-oxopropyl} -17-oxoestra-1 (10), 2,4-trien-3 -yl] boronic acid,
No. 32 - [(15beta- [3- (cyclohexylamino) -3-oxopropyl] -17-oxoestra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 33 - [(15beta- (3-morpholin-4-yl-3-oxopropyl) -17-oxoestra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 34 - [(15beta- {3 - [(1,3-benzodioxol-5-ylmethyl) amino] -3-oxopropyl} -17-oxoestra-1 (10), 2,4-trien-3-yl] boronic acids
No. 35 - [17-oxo-15beta- (3-oxo-3-piperidin-1-ylpropyl) estra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 37 - [(15 beta-{3- [benzyl (methyl) amino] -3-oxopropyl) -17-oxoestra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 39 - [(15 beta- [3- (diethylamino) -3-oxopropyl] -17-oxoestra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 45 - [(15 beta-[3- (1,3-benzodioxol-5-ylamino) -3-oxopropyl] -17-oxoestra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 48 - [15alpha- [4- (cyclohexylamino) -4-oxobutyl] -17,17-difluoroestra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 49 - [15alpha- [4- (diethylamino) -4-oxobutyl] -17,17-difluoroestra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 50 - [15 alpha- {4 - [(1,3-benzodioxol-5-ylmethyl) amino] -4-oxobutyl} -17,17-difluoroestra-1 (10), 2,4-trien-3-yl] boronic acid
No. 51 - [15alpha- (4 - {[2- (3,4-dimethoxyphenyl) ethyl] (methyl) amino} -4-oxobutyl) -17,17-difluoroestra-1 (10), 2,4-trien- 3-yl] boronic acid,
No. 53 - [17,17-difluoro-15alpha- {4-oxo-4 - [(pyridin-3-ylmethyl) amino] butyl} estra-1 (10), 2,4-trien-3-yl] boronic acids
No. 54 - [15alpha- [4- (benzylamino) -4-oxobutyl] -17,17-difluoroestra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 57 - [17,17-difluoro-15alpha- (4-oxo-4-piperidip-1-ylbutyl) estra-1 (10), 2,4-trien-3-yl] boronic acid,
No. 58 - [17,17-difluoro-15 beta- {3 - [(5-methyl-1,3-thiazol-2-yl) amino] -3-oxopropyl} estra-1 (10), 2,4-triene -3-yl] boronic acid,
No. 75 - 3 - {[3-methoxy-5- (trifluoromethyl) phenyl] amino} -15alpha- (4-morpholin-4-yl-4-oxobutyl) estra-1 (10) 2,4-trien-17one,
No. 76 - 15alpha- (4-morpholin-4-yl-4-oxobutyl) -3 - {[3- (morpholin-4-ylsulfonyl) phenyl] amino} estra-1 (10), 2,4-triene-17ona ,
No. 83 - 15alpha- (4-morpholin-4-yl-4-oxobutyl) -3- (quinolin-3-ylamino) estra-1 (10), 2,4-trien-17-one,
No. 91 - 3 - [(1,1-dioxo-1-benzothien-6-yl) amino] -15alpha- (4-morpholin-4-yl-4-oxobutyl) estra-1 (10), 2,4- trien-17-she
No. 98 - 3- (benzylamino) -15alpha- (4-morpholin-4-yl-4-oxobutyl) estra-1 (10), 2,4-trien-17-one
and any pharmaceutically acceptable salts thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06125138 | 2006-11-30 | ||
EP06125138.5 | 2006-11-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009124589A RU2009124589A (en) | 2011-01-10 |
RU2453554C2 true RU2453554C2 (en) | 2012-06-20 |
Family
ID=38198108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009124589/04A RU2453554C2 (en) | 2006-11-30 | 2007-11-27 | Substituted extratriene derivtives as 17beta hsd inhibitors |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2099814A1 (en) |
JP (1) | JP5264760B2 (en) |
CN (1) | CN101568547B (en) |
AU (1) | AU2007327653B2 (en) |
CA (1) | CA2671075A1 (en) |
HK (1) | HK1134298A1 (en) |
MX (1) | MX2009005201A (en) |
RU (1) | RU2453554C2 (en) |
WO (1) | WO2008065100A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012129673A1 (en) * | 2011-03-25 | 2012-10-04 | Universite Laval | INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 |
DE102011083725A1 (en) | 2011-09-29 | 2013-04-04 | Bayer Pharma AG | Estra-1,3,5 (10), 16-tetraene-3-carboxamide derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments |
WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
PE20150353A1 (en) | 2012-07-10 | 2015-03-28 | Bayer Pharma AG | DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAENO 3-SUBSTITUTED, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES |
KR20150118153A (en) | 2013-02-21 | 2015-10-21 | 바이엘 파마 악티엔게젤샤프트 | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3) |
EP3013847B1 (en) | 2013-06-25 | 2019-08-21 | Forendo Pharma Ltd | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1 |
US10377791B2 (en) | 2013-06-25 | 2019-08-13 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 |
AR096729A1 (en) * | 2013-06-25 | 2016-01-27 | Forendo Pharma Ltd | THERAPEUTICALLY ACTIVE DERIVATIVES OF ESTRATIEN-TIAZOL |
WO2016004166A1 (en) * | 2014-07-02 | 2016-01-07 | Xavier University Of Louisiana | Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group |
EP3237430B1 (en) | 2014-12-23 | 2019-03-20 | Forendo Pharma Ltd | PRODRUGS OF 17ß -HSD1 -INHIBITORS |
JP6523461B2 (en) * | 2014-12-23 | 2019-06-05 | フォレンド ファーマ リミテッド | Prodrugs of 17β-HSD1-inhibitors |
CZ307437B6 (en) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituted estrone derivatives as selective inhibitors of 17β-hydroxysteoid dehydrogenases |
FI3634975T3 (en) | 2017-06-08 | 2024-05-03 | Organon R&D Finland Ltd | 17-oximes of 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-ones for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases |
KR20210114390A (en) | 2018-12-05 | 2021-09-23 | 포렌도 파마 리미티드 | Estra-1,3,5(10)-triene compound condensed at position 16(17) with a pyrazole ring as an inhibitor of 17-HSD1 |
IT201900004041A1 (en) * | 2019-03-20 | 2020-09-20 | Farmabios Spa | Process for the preparation of a fulvestrant derivative |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571933A (en) * | 1994-11-17 | 1996-11-05 | Duquesne University Of The Holy Ghost | Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use |
US6541463B1 (en) * | 1998-03-11 | 2003-04-01 | Endorecherche, Inc. | Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0025788D0 (en) * | 2000-10-20 | 2000-12-06 | Sterix Ltd | Use |
TWI331154B (en) * | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
RU2412196C2 (en) * | 2005-05-26 | 2011-02-20 | Зольвай Фармасьютиклз Гмбх | 17β-HSD1 AND STS INHIBITORS |
US8030298B2 (en) * | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
-
2007
- 2007-11-27 CA CA002671075A patent/CA2671075A1/en not_active Abandoned
- 2007-11-27 RU RU2009124589/04A patent/RU2453554C2/en not_active IP Right Cessation
- 2007-11-27 CN CN200780048224.8A patent/CN101568547B/en not_active Expired - Fee Related
- 2007-11-27 MX MX2009005201A patent/MX2009005201A/en active IP Right Grant
- 2007-11-27 AU AU2007327653A patent/AU2007327653B2/en not_active Ceased
- 2007-11-27 EP EP07847383A patent/EP2099814A1/en not_active Withdrawn
- 2007-11-27 JP JP2009538695A patent/JP5264760B2/en not_active Expired - Fee Related
- 2007-11-27 WO PCT/EP2007/062856 patent/WO2008065100A1/en active Application Filing
-
2010
- 2010-01-21 HK HK10100621.5A patent/HK1134298A1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571933A (en) * | 1994-11-17 | 1996-11-05 | Duquesne University Of The Holy Ghost | Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use |
US6541463B1 (en) * | 1998-03-11 | 2003-04-01 | Endorecherche, Inc. | Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use |
Non-Patent Citations (1)
Title |
---|
AHVED et al // Bioorg. & Med. Chem. v. 14 no 24, p.8564-8573. * |
Also Published As
Publication number | Publication date |
---|---|
WO2008065100A1 (en) | 2008-06-05 |
CN101568547A (en) | 2009-10-28 |
MX2009005201A (en) | 2009-05-27 |
JP2010511010A (en) | 2010-04-08 |
AU2007327653B2 (en) | 2013-04-18 |
HK1134298A1 (en) | 2010-04-23 |
EP2099814A1 (en) | 2009-09-16 |
CN101568547B (en) | 2014-06-25 |
JP5264760B2 (en) | 2013-08-14 |
AU2007327653A1 (en) | 2008-06-05 |
CA2671075A1 (en) | 2008-06-05 |
RU2009124589A (en) | 2011-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2453554C2 (en) | Substituted extratriene derivtives as 17beta hsd inhibitors | |
RU2412196C2 (en) | 17β-HSD1 AND STS INHIBITORS | |
CN105873917B (en) | Non-steroidal antiandrogens and selective androgen receptor modulators containing a pyridyl moiety | |
US20040198773A1 (en) | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors | |
WO2003027105A1 (en) | Substituted 3-pyridyl thiophenes as c17,20 lyase inhibitors | |
JP2008545678A5 (en) | ||
US7662842B2 (en) | Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents | |
JP6088425B2 (en) | Cytochrome P450 inhibitors and uses thereof | |
JP6196302B2 (en) | 3-substituted estra-1,3,5 (10), 16-tetraene derivatives, methods for their preparation, pharmaceutical formulations containing them and their use for preparing medicaments | |
CN101472914A (en) | Inhibitors of C-FMS kinase | |
US20100022590A1 (en) | Novel compounds | |
JP2010511010A5 (en) | ||
EP3096762B1 (en) | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | |
US20040267017A1 (en) | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors | |
BRPI0619518A2 (en) | glucocorticoid receptor modulators, pharmaceutical compositions comprising them and uses thereof | |
CA2135056A1 (en) | New delta-17 and delta-20 olefinic and saturated 17b-substituted-4-aza-5a-andros-tan-3-ones as 5a-reductase inhibitors | |
WO2016017826A1 (en) | Xanthine oxidase inhibitor | |
US20040236110A1 (en) | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | |
KR20190129034A (en) | Metal Enzyme Inhibitor Compounds | |
BRPI0617851A2 (en) | beta-agonists containing indole, processes for its preparation and its use as a medicine | |
EP3237430B1 (en) | PRODRUGS OF 17ß -HSD1 -INHIBITORS | |
WO2008036067A2 (en) | Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents | |
EP3541812B1 (en) | Mglur7 agonist compounds for treating mglur7- regulated diseases, disorders, or conditions | |
CN110945007A (en) | 15 β - [ 3-propionylamino ] -substituted estra-1, 3,5(10) -trien-17-one compounds and 17-oximes thereof for inhibiting 17 β -hydroxysteroid dehydrogenase | |
US20040209924A1 (en) | Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20151128 |